<DOC>
	<DOCNO>NCT00815386</DOCNO>
	<brief_summary>Improvement heart failure moderate severe mitral regurgitation use percutaneously deliver implantable device reside coronary sinus</brief_summary>
	<brief_title>Safety Efficacy Study PTMA Device Reduce Mitral Valve Regurgitation Patients With Heart Failure</brief_title>
	<detailed_description>Device Test : The ViacorÂ® Percutaneous Transvenous Mitral Annuloplasty ( PTMA ) system comprise sterile implantable cardiac device associate custom accessory assist implantation . The PTMA system intend treat functional mitral regurgitation ( MR ) heart failure patient less invasive method surgical annuloplasty great relief symptom medical management alone . Study Objective : Functional mitral regurgitation associate adverse prognosis heart failure patient . The objective study evaluate whether PTMA effective reduce mitral regurgitation heart failure patient whether reduction associate moderation adverse progression heart failure symptom . Hypothesis Test : Reduction severity functional mitral regurgitation baseline , define composite improvement quantitative echocardiographic metric , achieve safely PTMA device associate measurable moderation adverse progression heart failure symptom moderation deterioration exercise capacity .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Patient moderate functional MR : regurgitant orifice area &gt; /= 0.20cm2 regurgitant volume &gt; /= 30 mL/beat regurgitant fraction &gt; /= 30 % Symptomatic heart failure NYHA Class II IV LV dysfunction ( 25 % &lt; LVEF &lt; 50 % echocardiography ) OR dilate mitral annulus &gt; 30mm MR organic origin Severe mitral leaflet tether History MI PCI within 60 day study procedure Inability walk minimum 100 meter 6 minute Significant leave main stenosis proximal circumflex stent Indication nonpatent CSO discontinuous CSGCVAIV Biventricular lead CS device impede device placement Severe aortic valvular disease Chronic corticosteroid use &lt; 20mg prednisone arthritis Significant comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>mitral valve</keyword>
	<keyword>heart failure</keyword>
	<keyword>mitral regurgitation</keyword>
	<keyword>annuloplasty</keyword>
	<keyword>coronary sinus</keyword>
</DOC>